Conolidine’s analgesic results stem from its conversation with non-opioid pain pathways. As opposed to opioids, which bind to µ-opioid receptors while in the central nervous program, conolidine modulates alternate molecular targets. A Science Improvements analyze found that conolidine interacts with the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide https://peterh429zbb9.frewwebs.com/profile